38216-93-2

Basic information

• Product Name: Propanal, 2,2-dimethyl-3-(phenylmethoxy)-
• Synonyms: 2,2-Dimethyl-3-(phenylmethoxy)-propionaldehyde;3-benzyloxy-2,2-dimethyl-1-propanal;3-benzyloxy-2,2-dimethylpropionaldehyde;3-benzyloxy-2,2-dimethylpropanal;3-benzyloxypivalic aldehyde;Propanal,2,2-dimethyl-3-(phenylmethoxy)
• CAS NO: 38216-93-2
• Molecular Formula: C12H16O2
• Molecular Weight: 192.258
• Mol File: 38216-93-2.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 283.2±15.0 °C(Predicted)
• Density: 1.001±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Propanal, 2,2-dimethyl-3-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanal, 2,2-dimethyl-3-(phenylmethoxy)-(38216-93-2)
• EPA Substance Registry System: Propanal, 2,2-dimethyl-3-(phenylmethoxy)-(38216-93-2)

Safety Data

• Hazardous Substances Data: 38216-93-2(Hazardous Substances Data)

Upstream product

• 774-48-1 (diethoxymethyl)benzene 
• 100-39-0 benzyl bromide 
• 14002-80-3 Methyl 2,2-dimethyl-3-hydroxypropionate 
• 96556-40-0 methyl-3-(benzyloxy)-2.2-dimethylpropionate 
• 100-44-7 benzyl chloride 
• 100-52-7 benzaldehyde 
• 126-30-7 2,2-Dimethyl-1,3-propanediol 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 776-88-5 5,5-dimethyl-2-phenyl-[1,3]dioxane 
• 75-24-1 trimethylaluminum 
• 66582-32-9 3-(benzyloxy)-2,2-dimethylpropan-1-ol 

Downstream Products

• 957791-46-7 (3R,4S)-3-acetoxy-4-(2-benzyloxy-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 865154-57-0 (3S,4R)-4-(2-benzyloxy-1,1-dimethylethyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one 
• 865154-54-7 (3R,4S)-3-hydroxy-4-(2-benzyloxy-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-44-5 (3R,4S)-3-hydroxy-4-(1,1-dimethyl-2-hydroxyethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-56-9 (4R)-4-(2-benzyloxy-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidine-2,3-dione 
• 957791-68-3 (3R,4S)-4-(2-benzyloxy-1,1-dimethylethyl)-3-(tert-butyldimethylsilanyloxy)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-70-7 (3R,4S)-3-(tert-butyldimethylsilanyloxy)-4-(1,1-dimethyl-2-hydroxy-ethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-72-9 (3R,4S)-3-(tert-butyldimethylsilanyloxy)-4-(1-formyl-1,1-dimethylmethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-74-1 (3R,4S)-3-(tert-butyldimethylsilanyloxy)-4-(2-(tert-butyldimethylsilanyloxy)-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 1328886-26-5 C₂₃H₃₀O₃ 
• 1328886-27-6 C₂₂H₂₈O₄ 
• 1328886-28-7 C₄₂H₅₄O₆Si 
• 1328886-36-7 C₄₂H₅₆O₆Si 
• 1404379-88-9 C₁₆H₂₂O₃ 

Relevant articles and documents

Synthesis and 5-lipoxygenase inhibitory activity of 7,7-dimethyleicosa-5Z,8Z-dienoic acid

-

Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans

Leishmaniases are neglected diseases that can be treated with a limited drug arsenal; the development of new molecules is therefore a priority. Recent evidence indicates that endoperoxides, including artemisinin and its derivatives, possess antileishmanial activity. Here, 1,2-dioxanes were synthesized with their corresponding tetrahydropyrans lacking the peroxide bridge, to ascertain if this group is a key pharmacophoric requirement for the antileishmanial bioactivity. Newly synthesized compounds were examined in vitro, and their mechanism of action was preliminarily investigated. Three endoperoxides and their corresponding tetrahydropyrans effectively inhibited the growth of Leishmania donovani promastigotes and amastigotes, and iron did not play a significant role in their activation. Further, reactive oxygen species were produced in both endoperoxide-and tetrahydropyran-Treated promastigotes. In conclusion, the peroxide group proved not to be crucial for the antileishmanial bioactivity of endoperoxides, under the tested conditions. Our findings reveal the potential of both 1,2-dioxanes and tetrahydropyrans as lead compounds for novel therapies against Leishmania.

PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES

The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.